1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

08 Apr 2024
Admin
News Article

Partner Therapeutics’ Leukine® (Sargramostim) Gets Approval in Japan

Partner Therapeutics’ Leukine® (sargramostim) Granted Approval in Japan for Treating Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Overview

Partner Therapeutics, Inc. (PTx) has recently announced that Nobelpharma, its partner, has received approval from the Japanese Pharmaceuticals and Medical Device Agency (PMDA) for the inhaled use of Leukine (sargramostim), which is branded as Sargmalin in Japan, for the treatment of aPAP (autoimmune pulmonary alveolar proteinosis). In 2022, PTx licensed certain indications rights for Japan to Nobelpharma. Leukine, a recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced via recombinant DNA technology in yeast, has not yet been approved for aPAP treatment via inhalation outside Japan. PTx will be manufacturing Sargmalin for Nobelpharma at its facility in Lynnwood, WA.

PAGE Trial Behind Approval

The approval of Sargmalin is supported by data from the PAGE trial, a phase 2 multicenter study led by Sponsor-Investigator Koh Nakata MD, PhD, Project Professor at Niigata University Medical Dental Hospital.
This trial, which was randomized, double-blind, and placebo-controlled, involved 64 patients with mild to moderate aPAP.
Patients were randomly assigned to receive either 125 micrograms of Leukine or a placebo twice daily for seven days, followed by a seven-day break, for twelve two-week cycles.
The primary endpoint, improvement in alveolar–arterial oxygen gradient (A-aDO2) between baseline and week 25, showed significant enhancement (p=0.02).
Additionally, Leukine demonstrated greater improvements in secondary endpoints such as serum biomarkers KL-6, CEA, and monocyte chemoattractant protein-1 (MCP-1).

Words from Partner Therapeutics

Robert Mulroy, CEO of Partner Therapeutics, expressed gratitude towards Nobelpharma for their partnership and commitment to making Sargmalin available to aPAP patients in Japan. Mulroy also acknowledged the contribution of patients and doctors participating in the investigator-initiated clinical trial conducted by Dr. Nakata of Niigata University.

aPAP Mechanism and Consequences

The investigation into inhaled sargramostim for aPAP is based on the understanding that this disease is a progressive lung disorder primarily caused by GM-CSF signaling blockage due to the presence of GM-CSF autoantibodies.
This deficiency inhibits the differentiation of monocytes into alveolar macrophages, leading to surfactant accumulation in the lungs.
Consequently, patients suffer from low oxygen levels, breathing difficulties, and immune deficiency, with potential complications including serious infections, pulmonary fibrosis, respiratory failure, and death.
GM-CSF addresses these issues by promoting alveolar macrophage maturation and surfactant breakdown.

Whole Lung Lavage

Traditionally, Whole Lung Lavage (WLL) has been the standard treatment for aPAP.
However, it is a lengthy and invasive procedure requiring hospitalization, general anesthesia, and mechanical ventilation.
Despite providing short-term relief, WLL does not address the underlying alveolar macrophage dysfunction.
LEUKINE
LEUKINE (sargramostim) is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in yeast.
It is commercially available in the United States and accessible internationally through a named patient program operated by Tanner Pharma Group.